A Rapid Two-Step Iduronate-2-Sulfatatse Enzymatic Activity Assay for MPSII Pharmacokinetic Assessment

  • Mitra AzadehEmail author
  • Luying Pan
  • Yongchang Qiu
  • Ruben Boado
Research Report
Part of the JIMD Reports book series (JIMD, volume 38)


Clinical studies involving enzyme replacement therapies (ERTs) have increasingly utilized enzymatic activity assays to monitor efficacy and biofunction of the drug; as a result, these assays have become an important part of pharmacokinetic (PK) and pharmacodynamic assessments in ERT trials. This paper presents a two-step enzymatic activity assay for iduronate-2-sulfatase (I2S) (EC which we have optimized to fit in 1 day and to complete in less than 6 h. The rapid assay presented here is a significant improvement over the original two-step method with run time of 24 h which spanned 2 days. The resulting 1 day assay is efficient, robust, reproducible, and better suited for use in pharmacokinetic studies. The method was fully validated in accordance with regulatory agency guidelines so that it could be implemented in PK studies. Validation of the method required additional modifications to circumvent limitations surrounding the calculation of accuracy. This challenge was overcome by developing strategies to determine both the expected and the measured values of validation samples in activity units. Subsequently, the method was validated in accordance with the FDA guidance for the validation of quantitative ligand binding assays (LBAs). Results of method development and optimization with focus on evaluations aimed at reducing the total assay run time as well as a summary of method validation performance are presented in this publication.


Enzymatic activity assay ERT Hunter Syndrome I2S MPSII α-l-iduronidase 



Mitra Azadeh, Luying Pan, and Yongchang Qiu are full time employees of Shire. Ruben Boado is a full time employee of ArmaGen. We thank Eurofins Pharma Bioanalytics Services, St Charles, MO, USA, contracted by Shire to perform valiation of the two-step activity method, for their services. We also thank the Shire Discovery Therapeutic Group for providing the IDUA.


  1. Boado RJ et al (2014) Insulin receptor antibody-iduronate 2-sulfatase fusion protein; pharmacokinetics, anti-drug antibody, and safety pharmacology in rhesus monkeys. Biotechnol Bioeng 111(11):2317–2324CrossRefPubMedPubMedCentralGoogle Scholar
  2. DeSilva B et al (2003) Recommendations for bioanalytical method validation of ligand-binding assays to support pharmacokinetics assessment of macromolecules. Pharm Res 20(11):1885–1990CrossRefPubMedGoogle Scholar
  3. Hopwood JJ (1979) α-L-Iduronidase, β-D-glucuronidase, and sulfo-L-iduronate 2-sulfatase: preparation and characterization of radioactive substrate from heparin. Carbohydr Res 69:203–216CrossRefPubMedGoogle Scholar
  4. Inoue H et al (1982) Fluorometric determination of arylsulfatase A and B activities. Chem Pharm Bull 30(11):4140–4143CrossRefPubMedGoogle Scholar
  5. Johnson BA et al (2013) Diagnosing lysosomal storage disorders: mucopolysaccharidosis type II. Current Prot Hum Genetics. doi:  10.1002/0471142905.hg1714s79
  6. Lu JZ et al (2010) Genetic engineering of a biofunctional fusion protein with iduronate-2-sulfatase. Bioconjug Chem 21:151–156CrossRefPubMedGoogle Scholar
  7. Muenzer J et al (2006) A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med 8(8):465–473CrossRefPubMedGoogle Scholar
  8. Muenzer J et al (2007) A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome). Mol Gen Metab 90:329–337CrossRefGoogle Scholar
  9. Tolun AA et al (2012) A novel fluorometric enzyme analysis method for Hunter syndrome using dried blood spots. Mol Genetics Met 105:519–521CrossRefGoogle Scholar
  10. Voznyi YV et al (2001) A fluorimetric enzyme assay for the diagnosis of MPS II (Hunter disease). J Inhert Metab Dis 24:675–680CrossRefGoogle Scholar

Copyright information

© SSIEM and Springer-Verlag Berlin Heidelberg 2017

Authors and Affiliations

  • Mitra Azadeh
    • 1
    Email author
  • Luying Pan
    • 1
  • Yongchang Qiu
    • 1
  • Ruben Boado
    • 2
  1. 1.ShireLexingtonUSA
  2. 2.ArmaGen Inc.CalabasasUSA

Personalised recommendations